

# Julie M Shabto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7656055/publications.pdf>

Version: 2024-02-01

33  
papers

536  
citations

840776

11  
h-index

677142

22  
g-index

33  
all docs

33  
docs citations

33  
times ranked

1002  
citing authors

#	ARTICLE	IF	CITATIONS
1	The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced stage cancer treated with immunotherapy. <i>Cancer</i> , 2019, 125, 127-134.	4.1	120
2	Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. <i>BMC Cancer</i> , 2019, 19, 857.	2.6	88
3	Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. <i>Cancer</i> , 2020, 126, 575-582.	4.1	65
4	Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. <i>Oncologist</i> , 2020, 25, e528-e535.	3.7	44
5	Discharge characteristics and care transitions of hospitalized patients with COVID-19. <i>Healthcare</i> , 2021, 9, 100512.	1.3	33
6	Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2020, 25, e484-e491.	3.7	29
7	Review of Hygiene and Disinfection Recommendations for Outpatient Glaucoma Care: A COVID Era Update. <i>Journal of Glaucoma</i> , 2020, 29, 409-416.	1.6	22
8	Clinical course and outcomes of COVID-19 in rheumatic disease patients: a case cohort study with a diverse population. <i>Clinical Rheumatology</i> , 2021, 40, 2633-2642.	2.2	20
9	Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2021, 26, 1017-1025.	3.7	18
10	Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2021, 26, 397-405.	3.7	14
11	Characteristics and outcomes of COVID-19 positive patients with diabetes managed as outpatients. <i>Diabetes Research and Clinical Practice</i> , 2020, 164, 108229.	2.8	14
12	Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors. <i>Cancer Medicine</i> , 2020, 9, 2752-2760.	2.8	13
13	Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors. , 2021, 9, e002851.		12
14	Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. <i>Investigational New Drugs</i> , 2019, 37, 1198-1206.	2.6	11
15	Novel risk scoring system for metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (C).. <i>Journal of Clinical Oncology</i> , 2020, 38, 734-734.	1.6	7
16	Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 53-59.	1.9	4
17	Body mass index (BMI) and toxicities and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).. <i>Journal of Clinical Oncology</i> , 2019, 37, 613-613.	1.6	3
18	Access to Care for Infertile Men: Referral Patterns of Fertility Clinics in the United States. <i>Urology</i> , 2022, , .	1.0	3

#	ARTICLE	IF	CITATIONS
19	Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib. Cancer Treatment and Research Communications, 2021, 28, 100393.	1.7	2
20	Novel risk stratification criteria of metastatic renal cell carcinoma (mRCC) patients (pts) treated with immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology, 2019, 37, e16068-e16068.	1.6	2
21	Association between immune-related adverse events (irAEs) and clinical outcomes (CO) in advanced urothelial cancer patients (pts) treated with immunotherapy (IO).. Journal of Clinical Oncology, 2019, 37, 472-472.	1.6	2
22	Sites of metastases (mets) and their association with clinical outcomes (CO) in urothelial cancer patients (pts) treated with immunotherapy (IO).. Journal of Clinical Oncology, 2019, 37, 473-473.	1.6	2
23	The impact of COVID-19: variations in volumes and characteristics of retina surgeries. BMC Surgery, 2022, 22, 41.	1.3	2
24	Extraocular Extension of a Regressed Choroidal Melanoma after Vitrectomy and Scleral Buckle for Rhegmatogenous Retinal Detachment. Ophthalmology, 2022, 129, 275.	5.2	2
25	Association of baseline modified Glasgow Prognostic Score (mGPS) with survival outcomes in patients with metastatic urothelial cell carcinoma (mUCC) treated with immune checkpoint inhibitors (CPI).. Journal of Clinical Oncology, 2020, 38, 563-563.	1.6	1
26	Association of modified Glasgow Prognostic Score (mGPS) with survival outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (CPI).. Journal of Clinical Oncology, 2020, 38, 738-738.	1.6	1
27	Analysis of toxicity and clinical outcomes (CO) in full versus reduced dose cabozantinib (cabo) in metastatic renal cell carcinoma (mRCC) patients (pts).. Journal of Clinical Oncology, 2019, 37, 671-671.	1.6	1
28	Sites of metastasis (mets) and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).. Journal of Clinical Oncology, 2019, 37, 585-585.	1.6	1
29	Baseline modified Glasgow prognostic score (mGPS) in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology, 2021, 39, e16546-e16546.	1.6	0
30	Early change in blood-based biomarkers and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO).. Journal of Clinical Oncology, 2018, 36, e15022-e15022.	1.6	0
31	Association of inflammation and clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).. Journal of Clinical Oncology, 2019, 37, 612-612.	1.6	0
32	Inflammatory markers at baseline (C1) and cycle 3 (C3) and their association with clinical outcomes in urothelial cancer patients (pts) treated with immunotherapy (IO).. Journal of Clinical Oncology, 2019, 37, 390-390.	1.6	0
33	Referral Patterns for Infertile Men: Predictors of Continued Treatment by Reproductive Endocrinologist versus Referral to a Nearby Urologist. Urology Practice, 0, , .	0.5	0